Fig. 2From: Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinomaMean scale scores for key QLQ-C30 functional scales and key QLQ-OES18 swallowing scales until 24 months post-surgeryBack to article page